All consecutive patients aged 18 years or older with a confirmed diagnosis of HT after AIS between January 2012 and June 2022 were enrolled in this retrospective cohort study conducted at the Stroke Center of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
This study was approved by the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. The requirement for informed consent was waived as this was a retrospective study and all data were anonymous.
The diagnosis of first-ever AIS was confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) at admission. The exclusion criteria were: a diagnosis of hemorrhagic stroke or transient ischemic attacks; a previous history of biliary calculus, cholecystitis, or malignancy; serum transaminase concentration greater than twice the upper limit of the reference range within 6 months; hepatitis B or C virus positivity; chronic kidney disease (glomerular filtration rate < 60 mL min−1 1.73 m−2); ongoing infection or inflammation; alcoholism (consumption of at least 40 g alcohol/day for males and ≥ 20 g/day for females during the previous 3 months); having received intravenous thrombolytic therapy; failure to undergo a second CT/MRI scan; and incomplete medical records.
A final total of 408 consecutive patients diagnosed with HT after AIS, consisting of 247 with sHT and 161 with HT after thrombectomy (tHT), were included in this study. The same number of age- and sex-matched AIS inpatients without HT for each cohort were randomly selected from the Stroke Center of our institution between January 2017 and June 2022 as controls. All patients met the inclusion criteria.
This study was approved by the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. The requirement for informed consent was waived as this was a retrospective study and all data were anonymous.
The diagnosis of first-ever AIS was confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) at admission. The exclusion criteria were: a diagnosis of hemorrhagic stroke or transient ischemic attacks; a previous history of biliary calculus, cholecystitis, or malignancy; serum transaminase concentration greater than twice the upper limit of the reference range within 6 months; hepatitis B or C virus positivity; chronic kidney disease (glomerular filtration rate < 60 mL min−1 1.73 m−2); ongoing infection or inflammation; alcoholism (consumption of at least 40 g alcohol/day for males and ≥ 20 g/day for females during the previous 3 months); having received intravenous thrombolytic therapy; failure to undergo a second CT/MRI scan; and incomplete medical records.
A final total of 408 consecutive patients diagnosed with HT after AIS, consisting of 247 with sHT and 161 with HT after thrombectomy (tHT), were included in this study. The same number of age- and sex-matched AIS inpatients without HT for each cohort were randomly selected from the Stroke Center of our institution between January 2017 and June 2022 as controls. All patients met the inclusion criteria.
Free full text: Click here
